Douglas B. Evans

52.4k total citations · 9 hit papers
500 papers, 36.7k citations indexed

About

Douglas B. Evans is a scholar working on Oncology, Surgery and Cancer Research. According to data from OpenAlex, Douglas B. Evans has authored 500 papers receiving a total of 36.7k indexed citations (citations by other indexed papers that have themselves been cited), including 309 papers in Oncology, 197 papers in Surgery and 119 papers in Cancer Research. Recurrent topics in Douglas B. Evans's work include Pancreatic and Hepatic Oncology Research (264 papers), Neuroendocrine Tumor Research Advances (98 papers) and Cancer Genomics and Diagnostics (77 papers). Douglas B. Evans is often cited by papers focused on Pancreatic and Hepatic Oncology Research (264 papers), Neuroendocrine Tumor Research Advances (98 papers) and Cancer Genomics and Diagnostics (77 papers). Douglas B. Evans collaborates with scholars based in United States, Canada and Switzerland. Douglas B. Evans's co-authors include James L. Abbruzzese, Jeffrey E. Lee, Peter W. T. Pisters, Robert A. Wolff, Jason B. Fleming, Jean‐Nicolas Vauthey, Eddie K. Abdalla, Christopher H. Crane, Karen R. Cleary and James C. Yao and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Molecular Cell.

In The Last Decade

Douglas B. Evans

489 papers receiving 35.9k citations

Hit Papers

One Hundred Years After “... 1992 2026 2003 2014 2008 2015 2008 2009 2006 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
    2008 3.3k citations Manal M. Hassan, Jason B. Fleming et al. profile →
  2. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
    2015 1.4k citations Douglas B. Evans et al. profile →
  3. Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression
    2008 897 citations Douglas B. Evans et al. Cancer Research profile →
  4. Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
    2009 853 citations Douglas B. Evans et al. profile →
  5. Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
    2006 634 citations James L. Abbruzzese, Peter W. T. Pisters et al. profile →
  6. Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease
    2008 592 citations Peter W. T. Pisters, Douglas B. Evans et al. profile →
  7. Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the Pancreas
    1992 571 citations Douglas B. Evans profile →
  8. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.
    1999 564 citations Weixin Wang, James L. Abbruzzese et al. PubMed profile →
  9. Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
    2008 533 citations Douglas B. Evans, Peter W. T. Pisters et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Douglas B. Evans 23.1k 13.0k 10.8k 8.1k 7.0k 500 36.7k
Adel K. El‐Naggar 16.8k 0.7× 11.9k 0.9× 3.2k 0.3× 5.7k 0.7× 5.1k 0.7× 679 36.4k
Susan S. Devesa 11.5k 0.5× 7.8k 0.6× 4.2k 0.4× 8.0k 1.0× 3.5k 0.5× 205 30.5k
Murray F. Brennan 38.6k 1.7× 31.6k 2.4× 8.3k 0.8× 43.3k 5.3× 6.0k 0.9× 954 81.0k
William D. Travis 17.7k 0.8× 6.5k 0.5× 8.6k 0.8× 34.4k 4.2× 4.7k 0.7× 546 56.6k
Jeffrey E. Lee 14.8k 0.6× 9.5k 0.7× 5.2k 0.5× 5.6k 0.7× 4.2k 0.6× 418 22.0k
Luigi Mariani 10.6k 0.5× 7.5k 0.6× 3.4k 0.3× 8.8k 1.1× 8.2k 1.2× 451 32.0k
Masao Tanaka 17.2k 0.7× 14.6k 1.1× 5.8k 0.5× 6.8k 0.8× 4.2k 0.6× 1.2k 35.1k
Markus W. Büchler 36.9k 1.6× 23.9k 1.8× 9.4k 0.9× 14.7k 1.8× 7.7k 1.1× 1.1k 56.5k
Christine M. Lohse 7.0k 0.3× 8.7k 0.7× 4.9k 0.5× 16.4k 2.0× 4.1k 0.6× 618 32.3k
Martin Schlumberger 9.0k 0.4× 19.9k 1.5× 8.0k 0.7× 3.7k 0.5× 3.8k 0.5× 387 50.2k

Countries citing papers authored by Douglas B. Evans

Since Specialization
Citations

This map shows the geographic impact of Douglas B. Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas B. Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas B. Evans more than expected).

Fields of papers citing papers by Douglas B. Evans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas B. Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas B. Evans. The network helps show where Douglas B. Evans may publish in the future.

Co-authorship network of co-authors of Douglas B. Evans

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas B. Evans. A scholar is included among the top collaborators of Douglas B. Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas B. Evans. Douglas B. Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Evans, Douglas B., et al.. (2024). Surgeon compensation in academic medicine. Surgery. 175(6). 1611–1618. 7 indexed citations
2.
Tolat, Parag, Naveen Kulkarni, Mohammed Aldakkak, et al.. (2024). Median arcuate ligament release at the time of pancreaticoduodenectomy or total pancreatectomy. Surgery. 175(5). 1386–1393. 1 indexed citations
3.
Dream, Sophie, Kara Doffek, Tina Yen, et al.. (2024). Persistent elevation of parathyroid hormone after curative parathyroidectomy: A risk factor for recurrent hyperparathyroidism. World Journal of Surgery. 49(1). 148–158. 1 indexed citations
4.
Fonseca, Ana Sofia, Alexis Vignes, Neeraj Shandilya, et al.. (2023). 109 Inter- and Intra-Laboratory Comparison of 6 Dustiness Testing Methods: Towards the Development of an OECD Testing Guideline. Annals of Work Exposures and Health. 67(Supplement_1). i97–i97. 1 indexed citations
5.
Aldakkak, Mohammed, Kathleen K. Christians, Callisia N. Clarke, et al.. (2023). Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity. Journal of Surgical Oncology. 128(1). 41–50. 2 indexed citations
6.
Dream, Sophie, James W. Findling, William S. Rilling, et al.. (2022). Wide Variability in Catecholamine Levels From Adrenal Venous Sampling in Primary Aldosteronism. Journal of Surgical Research. 277. 1–6. 4 indexed citations
7.
Gu, Junchen, Cindy Wang, Carolyn Cao, et al.. (2021). DGKζ exerts greater control than DGKα over CD8 + T cell activity and tumor inhibition. OncoImmunology. 10(1). 1941566–1941566. 10 indexed citations
8.
Yen, Tina, et al.. (2021). An Institutional experience with primary hyperparathyroidism in the elderly over two decades. The American Journal of Surgery. 222(3). 549–553. 9 indexed citations
9.
Dream, Sophie, et al.. (2021). Selective Glucocorticoid Replacement Following Unilateral Adrenalectomy for Hypercortisolism and Primary Aldosteronism. The Journal of Clinical Endocrinology & Metabolism. 107(2). e538–e547. 25 indexed citations
10.
Wang, Tracy, et al.. (2021). The Clinical Utility of Preoperative Thyroglobulin for Surgical Decision Making in Thyroid Disease. Journal of Surgical Research. 270. 230–235. 3 indexed citations
11.
Geurts, Jennifer L., et al.. (2020). Screening guidelines and recommendations for patients at high risk of developing endocrine cancers. Journal of Surgical Oncology. 121(6). 975–983. 6 indexed citations
12.
Gao, Chong, Ying Liu, Ben Staal, et al.. (2020). Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Clinical Cancer Research. 27(1). 226–236. 17 indexed citations
13.
Roy, Ishan, Donna McAllister, Noah P. Zimmerman, et al.. (2015). Pancreatic Cancer Cell Migration and Metastasis Is Regulated by Chemokine-Biased Agonism and Bioenergetic Signaling. Cancer Research. 75(17). 3529–3542. 52 indexed citations
14.
Li, Zhongkui, Zhe Chang, Ya’an Kang, et al.. (2009). TrkBT1 Induces Liver Metastasis of Pancreatic Cancer Cells by Sequestering Rho GDP Dissociation Inhibitor and Promoting RhoA Activation. Cancer Research. 69(19). 7851–7859. 45 indexed citations
15.
Kouvaraki, Maria A., Anita L. Korapati, George Z. Rassidakis, et al.. (2006). Potential Role of Jun Activation Domain–Binding Protein 1 as a Negative Regulator of p27kip1 in Pancreatic Adenocarcinoma. Cancer Research. 66(17). 8581–8589. 55 indexed citations
16.
Treviño, José G., Michael J. Gray, Justin M. Summy, et al.. (2006). Interleukin-8 is regulated by a Src/STAT3 pathway in pancreatic adenocarcinoma cells that is NF-κB independent. Cancer Research. 66. 1135–1135. 1 indexed citations
17.
18.
Chang, Ping, Manal M. Hassan, James L. Abbruzzese, et al.. (2004). Background and H2O2-induced micronuclei in peripheral blood lymphocytes as a risk factor for pancreatic cancer. Cancer Research. 64. 454–454. 3 indexed citations
19.
Raijman, Isaac, Iqbal Siddique, Jaffer A. Ajani, et al.. (1998). Palliation of malignant gastric outlet and duodenal obstruction using expandable metallic stents. Gastrointestinal Endoscopy. 47(4). 2 indexed citations
20.
Grau, Ana M., Ling Zhang, Weixin Wang, et al.. (1997). Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells.. PubMed. 57(18). 3929–34. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Adel K. El‐Naggar Breakdown of academic impact, for papers by Susan S. Devesa Breakdown of academic impact, for papers by Murray F. Brennan Breakdown of academic impact, for papers by William D. Travis Breakdown of academic impact, for papers by Jeffrey E. Lee Breakdown of academic impact, for papers by Luigi Mariani Breakdown of academic impact, for papers by Masao Tanaka Breakdown of academic impact, for papers by Markus W. Büchler Breakdown of academic impact, for papers by Christine M. Lohse Breakdown of academic impact, for papers by Martin Schlumberger
Rankless by CCL
2026